Krebs Biochemicals & Industries Limited has issued a clarification to BSE Limited regarding significant movement in its share price, stating that no material events warrant disclosure under regulatory requirements.

Regulatory Inquiry Response

The company responded to BSE's inquiry dated April 8, 2026, which sought clarification on the notable price movement in the company's securities. The exchange's communication, bearing reference number L/SURV/ONL/PV/APJ/2026-2027/3564, prompted the company to provide an official statement on April 10, 2026.

Company's Official Statement

In its clarification, Krebs Biochemicals & Industries Limited explicitly stated that there are no material information or material events that required disclosure or announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized that, in its opinion, no undisclosed developments have influenced the recent price movement in its securities.

Compliance Commitment

The company reaffirmed its commitment to regulatory compliance, noting that it has been regularly disseminating relevant information and details whenever required. This practice aligns with the company's obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The clarification was signed by Rakesh R Kalbate, Company Secretary & Compliance Officer, demonstrating the company's formal approach to addressing regulatory inquiries and maintaining transparency with market participants and stakeholders.

Krebs Biochemicals & Industries Limited has filed its mandatory compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate was submitted to stock exchanges on April 7, 2026, fulfilling the company's regulatory obligations under the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The company submitted the required documentation to both major Indian stock exchanges where its shares are listed. The filing includes certificates from KFIN Technologies Limited, which serves as the company's Registrar and Share Transfer Agent.

Certificate Verification

KFIN Technologies Limited, acting as the Registrar to an Issue and Share Transfer Agent, provided separate certificates to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These certificates confirm that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where the company's shares are listed.

The certificates were issued on April 1, 2026, and signed by Praveen Chaturvedi, Senior Vice President at KFIN Technologies Limited. Both depositories received identical confirmations regarding the company's compliance with the regulatory requirements.

Company Authorization

The submission was authorized by Rakesh R Kalbate, Company Secretary & Compliance Officer of Krebs Biochemicals & Industries Limited. The filing was digitally signed and includes the company's registered address at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh.

KFIN Technologies Role

KFIN Technologies Limited operates from multiple locations, with its operations centre in Hyderabad's Financial District and registered office in Mumbai. The company serves as the registrar and share transfer agent, ensuring compliance with SEBI regulations for securities dematerialization and rematerialization processes.

This quarterly filing represents part of the standard regulatory framework that listed companies must follow to maintain transparency in their securities transactions and depositories operations.